ArticleNeuro-oncology advances
Electronic assessment of health-related quality of life in glioblastoma patients using the EORTC-QLQ-C30/EORTC-BN20 and the PROMIS system in clinical practice.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation.Contemporary clinical trials communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patient-reported outcomes (PROs) are crucial for guiding patient care and maintaining quality of life This study assesses the feasibility of computer-based adaptations of the Patient-Reported Outcomes Measurement Information System (PROMIS) in a clinical setting and compares its outcomes with the EORTC-QLQ-C30 and EORTC-BN20 questionnaires. Validated, modular computer adaptive testing might reduce patient survey burden and provide physicians with more precise PROs. Methods: Newly diagnosed glioblastoma (GBM) patients were prospectively enrolled prior to radiation to evaluate feasibility. PROMIS modules were selected to reflect EORTC-QLQ-C30 and EORTC-BN20 domains, including anxiety, depression, fatigue, physical function, sleep disturbance, social satisfaction, cognitive ability, and global health. Patients completed both EORTC and PROMIS questionnaires electronically, preceding descriptive analyses. Results: Forty-three patients with 124 responses were analyzed. 31 patients completed surveys before or within 14 days of radiation, and 12 were outside the radiation window, yielding 60 completed surveys. Median completion times for the EORTC-QLQ-C30 and EORTC-BN20 were 4.77 (range: 2.05-18.6) and 2.63 (range: 1.17-24.83) min, respectively. For most PROMIS modules, completion times ranged from 0.6 to 1 min (range: 0.15-7.77), while global health took a median of 2.35 min (range: 1.02-21.12), The average time to completion was 8.65 min (range: 3.32-66.01). For most variables, PROMIS and EORTC-QLQ-C30 showed strong to moderate correlations. Conclusions: PROMIS measures correlated well with EORTC instruments, making them a suitable tool for evaluating patients with GBM. Response times were generally short, but variability suggested that low computer literacy, limited internet access, and disease burden may affect involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.